{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"-Time to neutrophil engraftment is measured by determining the first of 3 consecutive measurements of neutrophil count ≥ 500/ul following conditioning regimen induced nadir.","groups":[{"description":"Conditioning Regimens\n\n* fludarabine and busulfan +/- thymoglobulin\n* fractionated total body irradiation and cyclophosphamide\n* busulfan and cyclophosphamide\n* single dose total body irradiation and cyclophosphamide\n\nDay -2 = GvHD prophylaxis\n\nDay 0 or +1 = PBSC transplant\n\nDay +7 until neutrophil engraftment = G-CSF 5 ug/kg/day","id":"OG000","title":"Arm 2 - Recipient"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to Day 21","title":"Determine if Peripheral Blood Stem Cell Products Collected After Mobilization With IV Plerixafor Can be Used Safely for Hematopoietic Cell Transplantation in HLA-matched Recipients as Measured by Time to Neutrophil Engraftment (Recipient Only)","type":"SECONDARY","unitOfMeasure":"Participants"}